US pharma major Eli Lilly (NYSE: LLY) and Indian drugmaker Strides Arcolab (BO: 532531) have entered into a collaboration to expand delivery of cancer medicines in the emerging markets.
As a part of this arrangement, Lilly will in-license a portfolio of high-quality, branded generic injectable and oral cancer drugs from Agila Specialties, a division of Strides Arcolab, based in Bangalore, India.
Agila Specialties will manufacture the cancer medicines, and Lilly will register and market these medications in multiple geographies across the emerging markets. In addition to the initial 10 medicines included as part of the agreement, Lilly has the right to add additional high-quality branded generic oncology products to the portfolio in the future.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze